The High "Cost" of Experimental Drugs Obtained Through Health Litigation in Brazil

• Egile Nagusiak: Ricardo Eccard da Silva (Egilea), Elisangela da Costa Lima (Egilea), Maria Rita C. G. Novaes (Egilea), Claudia G. S. Osorio- (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

BackgroundBrazilian patients have legal right to access unlicensed medicines undergoing clinical research, if there is evidence of efficacy and safety. This study investigated the occurrence of serious adverse events related to very high-cost medicines from clinical studies, expanded access and comp...